BSE filing, NSE: BALPHARMA. Summary written from the filing by ALFA Finder's alert engine.
Bal Pharma Ltd: key numbers
- Share price
- ₹86.17
- Market cap
- ₹137.2 Cr
- Revenue (annual)
- ₹311.7 Cr
- Net profit (annual)
- ₹6.28 Cr
- P/E (TTM)
- 19.0×Sector 46.1×
- Promoter holding
- 50.86%+0.00% QoQ
- FII holding
- 0.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Bal Pharma Ltd
All →Bal Pharma Dividend
Bal Pharma disbursed its FY25-26 final dividend of ₹1.20 per share on October 9, 2026. Dividends for shareholders with incomplete KYC or bank details have been withheld.
Bal Pharma Management Change
Bal Pharma Limited announced a change in designations for directors Ravindra Kumar Kothari and Virupakshaya Himesh, effective October 1, 2026.
Bal Pharma Annual General Meeting
Bal Pharma Ltd held its 39th Annual General Meeting on September 24, 2026, where shareholders transacted all business items as per the notice.
Bal Pharma Price Movement Clarification
Bal Pharma has clarified that the recent significant movement in its share price is purely market-driven and not due to any undisclosed price-sensitive information.
Bal Pharma Other Announcement
Bal Pharma Ltd has filed its quarterly shareholding pattern for the period ended March 31, 2026, in compliance with SEBI regulations.
Bal Pharma Capital Structure Change
Bal Pharma Ltd allotted 10,00,000 convertible warrants to its promoter, Mr. Shailesh Siroya, at ₹84 per warrant. This preferential issue aggregates to ₹8.4 Crore.
- Value
- ₹8.40 Cr
Other other announcement announcements
All →ACME Solar Holdings Other Announcement
ACME Solar filed the CARE Ratings monitoring agency report on its Rs.2,800 crore QIP for the quarter ended 30 September 2026. The report shows no deviation from the offer objects.
eMudhra Other Announcement
eMudhra Ltd disclosed that SES ESG revised its ESG score from 68.0 to 64.9 in its ESG Report 2026. The company states it did not engage SES ESG, and the revision relates to its certificate business.
Aarti Pharmalabs Other Announcement
Aarti Pharmalabs has intimated under Regulation 46 that it revamped its website at the existing URL to improve design and accessibility. The notice has no financial or business substance.
Sagarsoft (India) Other Announcement
Sagarsoft (India) filed its Regulation 32 fund utilisation statement for its 2021 preferential issue. No deviation was reported and the full Rs.5.08 Crore was used.
Sadhana Nitro Chem Other Announcement
Sadhana Nitro Chem reported no deviation in use of its preferential issue proceeds for the quarter ended September 2026. The Audit Committee reviewed the statement.
Shriram Asset Management Company Other Announcement
Shriram AMC filed ICRA's quarterly monitoring agency report on preferential issue proceeds. Utilisation is in line with the offer objects, with no deviation reported.